Please login to the form below

Not currently logged in
Email:
Password:

Pfizer reveals sunitinib/ erlotinib trial data for lung cancer

Pfizer reveals global phase III clinical trials to evaluate the efficacy and safety of sunitinib in combination with erlotinib in previously treated patients with advanced non-small cell lung cancer

US-headquartered Pfizer has revealed global phase III clinical trials to evaluate the efficacy and safety of sunitinib in combination with erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC) at the International Association for the Study of Lung Cancer (IASLC) World Conference in Korea.

Pfizer Oncology initiated the phase III study to evaluate the potential role of sunitinib in previously treated patients with advanced NSCLC. The randomised, double-blind trial of 956 patients was designed to compare the overall survival of patients taking sunitinib combined with erlotinib with those taking erlotinib plus placebo.

Secondary endpoints of the study included progression-free survival, objective response rate, one-year survival, duration of response, adverse events and patient-reported outcomes.
 
Also revealed at the IASLC were phase III trials to evaluate the role of sunitinib in the treatment of various solid tumours including advanced breast cancer (BC), advanced non-small cell lung cancer (NSCLC) and advanced colorectal cancer (CRC).

Pfizer Oncology presented preliminary results from a phase II study, which revealed the safety and tolerability of sunitinib in combination with erlotinib in patients with advanced NSCLC.

As of August 2007, two patients had experienced a partial response (PR). The tolerability and activity observed in the lead-in cohort supported the randomised phase II portion of this study, which is now enrolling to evaluate this combination in NSCLC in more detail.

Dr Charles Baum, head of oncology development at Pfizer, said: ìWe are encouraged by the early data we are seeing for sunitinib in NSCLC. Pfizer is committed to further exploring the potential role of sunitinib in advanced NSCLC through the initiation of SUN 1087, a global, phase III study.î

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics